Calycosin

Calycosin

Calycosin is a naturally occurring isoflavone — a subclass of polyphenolic flavonoid compound — derived principally from the roots of Astragalus membranaceus and related species. It has attracted substantial scientific attention over the past two decades for its diverse pharmacological activities, which span anticancer, anti-inflammatory, neuroprotective, cardioprotective, antidiabetic, and estrogenic-like properties. The overwhelming majority of evidence characterizing calycosin's biological effects comes from in vitro cell culture experiments and animal models; human clinical trials remain scarce, and calycosin has not been approved as a pharmaceutical drug by any major regulatory authority.

Identity and Chemical Characterization

Chemical Names and Classification

Calycosin is an O-methylated isoflavone. It is a purified isoflavone with the molecular formula C₁₆H₁₂O₅, and its IUPAC name is 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-chromen-4-one. It is also designated by the systematic descriptor 7,3′-dihydroxy-4′-methoxy isoflavone (C₁₆H₁₂O₅). Calycosin belongs to the family of 7-hydroxy isoflavones, in which an extra hydroxy group replaces the 3′ position and a methoxy group occupies the 4′ position; it is simultaneously a member of both the 7-hydroxyisoflavone and the 4′-methoxyisoflavone subclasses.

The molecular weight of calycosin is 284.26 g/mol, and computed physicochemical parameters include a QPlogPo/w of 1.5, two hydrogen bond donors (HBD), and five hydrogen bond acceptors (HBA), collectively indicating good drug-likeness properties.

Biosynthesis

Isoflavone 3′-hydroxylase uses formononetin, NADPH, H⁺, and O₂ to produce calycosin, NADP⁺, and H₂O. The enzyme responsible in Astragalus membranaceus, designated AmI3′H, has been functionally characterized; transcriptome-based prediction has identified AmbHLH30 as a potential transcription factor regulating calycosin biosynthesis, and red light not only promotes calycosin accumulation but also modulates the expression of biosynthetic genes and transcriptional regulators.

Physical Form

In its pure form, calycosin is a white needle-like crystal that displays poor solubility in water and various organic solvents, including ethanol, methanol, and chloroform; it also shows poor solubility in acetone and dichloromethane. This low solubility has driven interest in nanocarrier-based delivery systems to enhance its bioavailability.

Natural Sources and Botanical Context

Primary Sources

Calycosin is the most enriched isoflavone found abundantly in Astragalus. It is a bioactive phytoestrogen isoflavone extracted from traditional Chinese medicinal plants such as Astragalus membranaceus, Hedysarum polybotrys, Glycyrrhiza glabra, and Spatholobi Caulis, with the highest content of calycosin found in Astragalus membranaceus.

It can also be found in various other plant sources within the Fabaceae (legume) family, including Thermopsis lanceolata, Hedysarum polybotrys, Trifolium pratense L. (red clover), Astragalus falcatus, A. microcephalus, Wisteria brachybotrys, Thermopsis californica, Bowdichia nitida, Styphnolobium japonicum, Mucuna membranacea, Andira surinamensis, Myroxylon peruiferum, Calycotome villosa, and Oxytropis falcata, among others.

The Source Plant: Astragalus membranaceus

Astragalus L. is the largest genus in the family Leguminosae, comprising approximately 2,900 species. Astragalus membranaceus (Fisch.) Bunge and Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge) Hsiao are used worldwide because of their high medicinal and nutritional value. Astragali Radix (Huangqi), the dried roots of A. membranaceus or Astragalus mongholicus, is commonly used as a herbal ethnopharmacological herb in China. Huangqi is mainly distributed in the Russian Federation, Mongolia, and China.

The chemical composition of Astragalus is complex and mainly includes flavonoids, saponins, and polysaccharide compounds, as well as amino acids and trace elements. To date, more than 200 compounds have been isolated from Astragalus species, among which isoflavones such as calycosin (CAL), calycosin-7-glucoside (CG), formononetin (FMN), and ononin (ON) have significant value because of their significant antioxidant, anticancer, anti-inflammatory, and neuroprotective pharmacological effects.

Traditional and Historical Use

Traditional Chinese Medicine (TCM)

Calycosin is not used as an isolated compound in traditional medicine; rather, it is ingested as an integral constituent of the whole-plant preparations of Radix Astragali (Huangqi). The application of Huangqi can be traced back to the Han Dynasty and was first recorded in the Shennong Ben Cao Jing (Han Dynasty, BCE 202–220), where it was categorized as a high-quality product. Radix Astragali is one of the most famous traditional Chinese herbal medicines, and this herb has been used as a medicine for more than 2,000 years.

Astragalus membranaceus (Fabaceae) has a long history of use as a traditional medicine in China, Japan, Korea, and other regions in Asia.

Within the framework of TCM, Huangqi was seen to tonify both active energies (qi) and those that build resilience (xue or Blood), as well as supporting the Chinese concept of the Spleen — the function controlling assimilation in the body — thus being used where fatigue is linked to decreased appetite. Like other qi tonics, Huang Qi influences the Spleen and Lungs, for these are the primary organs responsible for the cultivation (via food and air, respectively) and dissemination of qi in the body.

Radix astragali has been widely used in TCM for the treatment of hypertension, diabetes, cirrhosis, nephritis, cancer, and many other disorders. The major pharmaceutical functions attributed to this Materia Medica within TCM are boosting the immune and hematopoietic systems. About 80% of clinical traditional Chinese medicine prescriptions contain Radix Astragali (RA, Huang Qi in Chinese), which was listed in the national drug and food homology in 2018 as having non-toxic effects.

Preparations in Traditional Use

The aqueous extracts of Huangqi are often used separately or in combination with other drugs to expand the range of its medicinal effects. Traditional preparations typically involve decocting the dried root in water to produce a tea or concentrated soup. Calycosin, being the predominant isoflavone in the root, is delivered to the body as part of this complex matrix, alongside polysaccharides, saponins, and other flavonoids. Astragalus mongholicus is listed as the top quality in the classic work of traditional Chinese medicine, Bencao Ganmu (Compendium of Materia Medica), known as "the most effective of tonic medicine," and is widely used in the classic prescriptions of TCM for clinical treatment of gastrointestinal diseases.

Key Active Constituents and Chemical Context Within the Source Plant

The major components of Astragalus membranaceus are polysaccharides, flavonoids, and saponins. Among the flavonoids, calycosin is the most important active flavonoid substance identified predominantly within this medicinal plant. Its glycoside form, calycosin-7-O-β-D-glucoside (also called calycosin-7-glucoside or CG), is also present in the plant and participates in the pharmacokinetic profile following oral consumption.

Calycosin co-occurs with structurally related isoflavones including formononetin (the biosynthetic precursor to calycosin), ononin, and 6-acetylononin, as well as triterpenoid saponins (astragalosides I, II, and IV) and Astragalus polysaccharides (APS), all of which contribute to the overall pharmacological profile of Radix Astragali preparations.

Mechanisms of Action

Phytoestrogenic Activity

Calycosin is a bioactive isoflavone phytoestrogen whose molecular structure is similar to estrogen; owing to this structural similarity, calycosin has both estrogenic and anti-estrogenic effects and can bind to estrogen receptors, exerting biological effects via genomic as well as non-genomic mechanisms.

Molecular docking studies have shown that calycosin can couple into the binding sites of both ERα and ERβ, and pretreatment with calycosin increases the expression levels of both ERα and ERβ. The context-dependent nature of this phytoestrogenic activity is important: the inhibitory action of calycosin on ER-positive breast cancer cells appears to be achieved through an increase in ERβ expression and subsequent regulation of the ERβ signaling pathway. Estrogen receptor contains two subtypes, ERα and ERβ; the proportion of ERα-positive cells in estrogen-dependent breast cancers is higher than that of normal breast tissue, whereas ERβ expression is decreased, indicating an antagonistic relationship between ERα and ERβ. Upregulation of ERβ may therefore inhibit the promotion of breast cancer.

PI3K/AKT/mTOR Signaling Pathway

Calycosin, when administered to estrogen receptor-positive human osteosarcoma cells in vitro and in mouse xenograft models, demonstrated anti-proliferative and pro-apoptotic effects, and at the molecular level achieved these effects through the PI3K/AKT/mTOR signaling pathway, in which PI3K was the key protein. This pathway modulation has been documented across numerous cancer cell types studied in vitro.

IGF-1R, p38 MAPK, and Downstream Apoptotic Cascades

With the upregulation of ERβ, successive changes in downstream signaling pathways were found in breast cancer cell models, including inactivation of insulin-like growth factor 1 receptor (IGF-1R), then stimulation of p38 MAPK and suppression of the serine/threonine kinase Akt, and finally PARP-1 cleavage. ERK1/2 and JNK pathways were not consequently regulated by downregulated IGF-1R, indicating these were not necessary for calycosin-mediated proliferation inhibition. Collectively, calycosin inhibits growth and induces apoptosis in ER-positive breast cancer cells through ERβ-induced inhibition of IGF-1R, along with selective regulation of MAPK and PI3K/Akt pathways.

NF-κB Inflammatory Pathway

Calycosin ameliorates diabetes-induced kidney inflammation by downregulating phosphorylation of p65 in the NF-κB signaling pathway; it can also regulate inflammation and promote bone formation by inhibiting the TLR4/NF-κB pathway; additionally, calycosin has been shown to maintain the epithelial barrier in atopic dermatitis by inhibiting the TLR4-mediated NF-κB pathway — collectively suggesting that calycosin mediates inflammatory damage across multiple disease contexts by regulating the TLR4/NF-κB signaling pathway.

WDR7-7 / GPR30 Signaling

Calycosin has been shown to inhibit the proliferation of both ER− and ER+ breast cancer cells, and these inhibitory effects are associated with the up-regulation of the long non-coding RNA (lncRNA) WDR7-7; the overexpression of WDR7-7 inhibits growth through a mechanism that involves G-protein-coupled estrogen receptor 30 (GPR30). This indicates that, in addition to ER-mediated signaling pathways, non-ER-mediated pathways are also involved in calycosin-mediated regulation of cancer cell proliferation.

Anti-Inflammatory and Antioxidant Mechanisms (Overview)

Calycosin has many pharmacological properties, including anti-inflammatory, antioxidant, anti-cancer, neuroprotective, and cardioprotective effects. Its anti-inflammatory property is mainly achieved by inhibiting or attenuating the effects of pro-inflammatory cytokines. Studies also highlight its potential for immunomodulation, anti-aging, anti-diabetes, and angiogenesis.

Multiple signal pathways are responsible for the effects of calycosin, including but not limited to the Nrf2/SLC7A11/GPX4 signaling, AMPK/mTOR signaling, KLF2-MLKL-mediated autophagy pathway, MAPK, STAT3, and NF-κB signaling.

Anti-Cancer Mechanisms (General Overview)

The anti-cancer mechanism of calycosin is mediated through a variety of processes, including regulation of apoptotic pathways, cell cycle arrest, inhibition of angiogenesis and metastasis, modulation of oncogenes and enzymatic pathways, and signal transduction processes. Calycosin influences various cellular processes that play a role in cancer development and progression, including cell cycle arrest, apoptosis induction, inhibition of angiogenesis, anti-inflammatory effects, metastasis suppression, hormone receptor modulation, inhibition of signaling pathways, and antioxidant properties; additionally, calycosin may work with other natural compounds and conventional chemotherapy drugs to enhance the activity of those drugs and alleviate resistance profiles.

Scientific Evidence by Area of Use

1. Oncology — Anticancer Activity

Based on current review evidence, calycosin has demonstrated activity against approximately 15 different types of cancer in experimental models. However, the overwhelming majority of this evidence is preclinical, derived from in vitro cell lines and animal xenograft models. Robust randomized controlled human clinical trials are not yet available for calycosin as an isolated compound.

Breast Cancer

Calycosin led to time- and dosage-dependent induction of growth inhibition and apoptosis in ER-positive MCF-7 and T-47D cells; it is likely that whether or not calycosin participates in growth regulation of breast cancer cells would mainly depend on the estrogen receptor present. Calycosin at 150 μM was capable of blocking MCF-7 and T47D cell migration and invasion in wound healing and Transwell assays, and calycosin at 2 μmol/L already triggered MCF-7 cell apoptosis by flow cytometry analysis; treatment also downregulated forkhead box P3, VEGF, and MMP9 in MCF-7 and T47D cells. These are in vitro findings only.

Calycosin also inhibited the proliferation of both ER− (MDA-MB-468 and SKBR3) and ER+ breast cancer cells (MCF-7 and T47D), and these inhibitory effects were associated with the up-regulation of the long non-coding RNA WDR7-7. Evidence strength: preliminary, in vitro and animal xenograft only.

Colorectal Cancer

Calycosin reduces colorectal cancer (CRC) cell viability, induces cell apoptosis, and suppresses xenograft tumor growth in laboratory models. Mechanistically, the effect of calycosin on the viability and apoptosis of human CRC HCT116 and SW480 cells was analyzed via MTT assay, flow cytometry assay, and caspase-3/7 activity assay, with the protein expressions of ERβ, PTEN, and PI3K/Akt signal pathway components being determined by Western blot analysis. Evidence strength: preclinical, in vitro and murine xenograft.

Lung Cancer

Some studies have depicted the impact of calycosin against lung cancer, demonstrating anti-tumor, neuroprotective, and anti-inflammatory properties. In one in vitro investigation, calycosin was shown to suppress the proliferation and metastatic potential of A549 (lung adenocarcinoma) cells, with various pharmacologic effects including antitumor, neuroprotective, and anti-inflammatory properties being reported, and prior studies demonstrating that calycosin inhibits cancer growth via apoptosis. Evidence strength: in vitro only.

Glioblastoma

One study investigated the potential anticancer effects of calycosin against human glioblastoma cells, including impacts on cell proliferation, apoptosis, cell cycle distribution, and its inhibitory activity on migration and invasion in U87 and U251 cells, demonstrating that TGF-β-mediated reductions of mesenchymal-associated genes, MMP-2, and MMP-9 were involved; administration of calycosin in a glioblastoma xenograft model showed that calycosin reduced tumor volume and suppressed TGF-β and its downstream molecules. Evidence strength: in vitro and animal model only.

Osteosarcoma

The effects of calycosin on apoptosis of estrogen receptor (ER)-positive and ER-negative human osteosarcoma cell lines and tumor xenografts in mice were investigated; cultured ER-positive MG-63 human osteosarcoma cells and ER-negative U2-OS cells were treated with increasing doses of calycosin (0, 25, 50, and 100 μM), and cell viability and apoptosis were studied by MTT assay and flow cytometry. Evidence strength: preclinical in vitro and murine.

2. Neuroprotection and Brain Disorders

Research has highlighted the neuroprotective effects of the phytoestrogen calycosin on cerebral ischemia-reperfusion injury (CIRI), and studies have aimed to explore the effects of calycosin on the HMGB1/TLR4/NF-κB signaling pathway in rat models of CIRI, both in vivo and in vitro. Previous studies have indicated that the phytoestrogen calycosin exerts neuroprotective effects in cerebral ischemia and reperfusion injury rats.

Research has indicated that both estrogens and phytoestrogens may positively influence brain function; the administration of phytoestrogens or estrogen replacement therapy has been shown to enhance cognitive function, delay the progression of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, and provide neuroprotection.

Calycosin has demonstrated antihypertensive and neuroprotective effects, and its effectiveness in the prevention and treatment of cardiovascular and neurodegenerative diseases has been studied.

Despite these promising findings, further research, including detailed mechanistic studies and clinical trials, is needed to fully understand calycosin's therapeutic mechanisms and validate its potential in human subjects; developing advanced delivery systems and exploring synergistic therapeutic strategies could further enhance its clinical application and effectiveness. Evidence strength: predominantly animal (rodent MCAO models) and in vitro; no human clinical trials identified.

3. Cardiovascular Protection

Calycosin and its derivatives have multiple biological effects, such as antioxidant, pro-angiogenesis, anti-tumor, antidiabetic, hepatoprotective, neuroprotective, and anti-inflammatory effects; calycosin has also shown promising cardioprotective effects, including the prevention of myocardial injury and improvement of heart function.

In studies of doxorubicin (DOX)-induced cardiotoxicity — a clinically important problem in cancer chemotherapy — calycosin (CAL) increased H9c2 cell viability and decreased DOX-induced pyroptosis via NLRP3, caspase-1, and gasdermin D signaling pathways in a dose-dependent manner; in vivo, CAL-DOX co-treatment effectively suppressed DOX-induced cytotoxicity as well as inflammatory and cardiomyocyte pyroptosis via the same molecular mechanism. Furthermore, calycosin suppressed DOX-induced mitochondrial oxidative stress injury in H9c2 cells by decreasing ROS generation and increasing mitochondrial membrane potential and ATP; it also attenuated DOX-induced increases in malondialdehyde content and decreased superoxide dismutase and glutathione peroxidase activities; in vivo, calycosin afforded a protective effect against DOX-induced cardiac injury by improving myocardial function and inhibiting brain natriuretic peptide.

Molecular docking showed that calycosin can couple into the binding sites of ERα and ERβ; calycosin diminished the effects of H₂O₂ in cardiomyocytes in a dose-dependent manner; pretreatment with ICI 182,780 (an estrogen receptor inhibitor) negated the protective effect of calycosin against H₂O₂-induced apoptosis.

A 2026 study explored calycosin's antithrombotic potential: calycosin selectively inhibited collagen-induced platelet aggregation and glycoprotein VI-mediated downstream signaling, including pathways involving phospholipase Cγ2 and protein kinase C. Evidence strength: in vitro and rodent models; no human trial data identified.

4. Anti-Inflammatory Effects

Calycosin shows potent antioxidative properties by reducing oxidative stress markers and increasing antioxidant enzyme activities; in recent years this natural compound has attracted significant scientific interest due to its diverse pharmacological and biomedical properties.

The NF-κB pathway is a central mechanism: across separate in vivo studies, calycosin has been shown to attenuate inflammatory damage in diabetic nephropathy, glucocorticoid-induced femoral head necrosis, atopic dermatitis, and renal ischemia-reperfusion injury through TLR4/NF-κB suppression. In a mouse model of diabetic nephropathy, db/db mice were intraperitoneally injected with 10 mg/(kg·d) calycosin or control saline for 4 weeks, followed by analysis of structural injury, inflammation, and NF-κB signaling activity.

In studies of acute pancreatitis using the cerulein mouse model, calycosin alleviated inflammatory injury via the p38 MAPK and NF-κB signaling pathways. Laboratory studies have identified anti-inflammatory, antioxidant, anti-tumor, and immunomodulatory effects as the fundamental properties of calycosin's efficacy. Evidence strength: animal (rodent) models and in vitro; no definitive human clinical trial data identified.

5. Bone Health and Osteoporosis

Calycosin has been reported to play a role in preventing osteoporosis in postmenopausal women. The active ingredient has been shown to stimulate osteoblast differentiation by modulating the GSK-3β pathway. Levels of specific markers of osteoblast differentiation, including alkaline phosphatase, alpha-1 type I collagen, and Runx2 protein, were significantly increased after exposure to calycosin. Furthermore, calycosin has been observed to stimulate the expression of osteoprotegerin, and correlated with the MAPK pathway, calycosin was able to abolish RANKL-induced osteoclast formation from primary bone marrow macrophages.

Calycosin is a phytoestrogen with a wide range of pharmacological activities; by affecting PI3K/Akt/mTOR, WDR7-7-GPR30, Rab27B-β-catenin-VEGF, and other signaling pathways, calycosin shows effects including anti-osteoporosis activity alongside its anticancer, anti-inflammatory, neuroprotective, and hepatoprotective properties. Evidence strength: primarily in vitro (cultured osteoblasts and osteoclasts) and animal models; direct human clinical data on fracture outcomes and bone density are lacking for calycosin as an isolated compound.

6. Diabetes and Metabolic Disorders

In the context of diabetic nephropathy, calycosin, as another active Chinese herbal extract from Radix Astragali, was studied for its therapeutic effects on diabetic nephropathy; Radix Astragali is widely administered to ameliorate the symptoms of diabetes as well as diabetic nephropathy, though its mechanism of action was not yet fully defined at the time of the study. In vitro and in vivo work demonstrated that calycosin suppressed inflammatory cytokine release via NF-κB downregulation in tubular epithelial cells in a diabetic mouse model.

Calycosin has been extensively studied for its multiple pharmacological properties, including anti-inflammatory, antioxidant, anti-osteoporosis, and anti-diabetic effects; it has been demonstrated to protect the heart, blood vessels, nerves, and liver from various forms of injury and disease.

In gestational diabetes mellitus (GDM), one study used a db/+ diabetic mouse model to evaluate the effects of calycosin administration on GDM symptoms, exploring how calycosin inhibits inflammation and enhances beta cell function by suppressing RNF38 expression. Evidence strength: animal models and in vitro; no robust human clinical trial data identified for isolated calycosin.

7. Hepatoprotection

Calycosin is a natural compound with antioxidant and anti-inflammatory activities extracted from Astragalus membranaceus; it exerts various pharmacological effects, including antitumor, hepatoprotective, and neuroprotective effects. Research in acute liver failure (ALF) cell models (LPS-induced L02 human liver epithelial cells) has explored the role of calycosin in suppressing the TLR4/NF-κB pathway to reduce hepatocyte apoptosis. It is important to note that one published paper on this topic (PMC10336678) was subsequently retracted; this should be borne in mind when evaluating the hepatoprotective evidence base. Additional work has documented anti-hepatic fibrosis effects in combination with astragaloside I and levistilide A. Evidence strength: in vitro and limited animal studies; retraction of one paper reduces the robustness of certain hepatoprotective claims.

8. Atherosclerosis

Anti-inflammatory, antioxidant, anti-tumor, and immune modulatory effects are the fundamental properties of calycosin's efficacy; a number of signaling pathways are responsible for its effects, including the Nrf2/SLC7A11/GPX4, AMPK/mTOR, KLF2-MLKL-mediated autophagy, MAPK, STAT3, and NF-κB pathways. In experimental atherosclerosis models, calycosin has been shown to suppress the activating effect of granulocyte-macrophage colony-stimulating factor-producing T helper cells on macrophages, identifying NR4A3 as a downstream target. Evidence strength: preclinical; no human clinical data identified.

Pharmacokinetics and Bioavailability

The pharmacokinetics of calycosin have been studied, and it displays the fastest absorption and elimination among four related isoflavones (calycosin, calycosin-7-O-β-D-glucoside, ononin, and formononetin) after oral administration of Astragalus membranaceus extract solution; the primary sites of calycosin metabolism are the intestine and liver, with the highest absorption and permeability observed in the colonic segment of the intestine; calycosin is primarily metabolized in the liver as flavonoid sugars, while those absorbed in the intestine are secreted into the intestinal lumen before reaching the liver, leading to its low bioavailability.

Because of hydroxyl groups found within the chemical structure of calycosin, they are metabolized to glucuronide by phase II metabolic enzymes such as UDP-glucuronosyltransferases from the intestine and liver after oral administration; in addition to metabolism, absorption, hydrolysis, efflux, and intestinal circulation in the intestinal tract also participate in the disposal of calycosin in the body, affecting its systemic and local bioavailability; studies have shown that after oral administration of Astragalus water extract, the enriched content of calycosin-7-O-β-glucoside is detected in plasma, indicating that calycosin-7-O-β-glucoside can enter intestinal cells in a prototype form and be metabolized.

Predicted in silico results suggest that calycosin might be highly absorbed orally and can be permeable by skin, intestine, and kidney cells. However, for drugs targeting brain disorders, the blood-brain barrier (BBB) is essential, and calycosin has a poor predicted potential to cross the blood-brain barrier and enter the central nervous system. This represents a notable pharmacokinetic limitation for proposed neuroprotective applications.

Different diseases, doses, and combination medications have a serious impact on calycosin metabolism, and glucuronidation is the main metabolic pathway of calycosin.

Dosage Forms and Doses Reported in Research

Calycosin is not approved as a pharmaceutical drug, and no standardized dosage has been established through clinical trials. The doses referenced below are solely as reported in the cited research studies.

• In vitro cell culture studies: Doses used in osteosarcoma cell line experiments included 0, 25, 50, and 100 μM. In breast cancer (MCF-7) apoptosis studies, calycosin at 2 μmol/L triggered apoptosis by flow cytometry analysis. In cell migration and invasion assays, calycosin at 150 μM was shown to block MCF-7 and T47D cell migration.
• Animal (in vivo) studies: In a diabetic nephropathy mouse model, db/db mice were intraperitoneally injected with 10 mg/(kg·d) calycosin for 4 weeks.
• Supplemental forms: Calycosin is available commercially as isolated purified powder, as standardized Astragalus root extracts standardized to calycosin content, and is a component of whole Astragalus root preparations (capsules, tablets, teas, and tinctures). Research groups have also explored nanocarrier delivery systems to improve the compound's inherently low aqueous bioavailability.

Although plant species containing calycosin are available, its therapeutic dose in humans has not been properly analyzed.

Safety Considerations and Drug Interactions

General Toxicity Profile

Calycosin has demonstrated medicinal potential across various diseases, including cancers, inflammation, and cardiovascular disease, and has been noted for its high targeting and low toxicity profile. Several studies have highlighted the potential of calycosin as an anti-metastatic agent in various tumors, promoting apoptosis in cancer cells while exhibiting low toxicity to normal cells. Nevertheless, these characterizations come primarily from in vitro and animal experiments; comprehensive human toxicology data are not established.

Calycosin's in silico toxicity profile has been predicted based on hepatotoxicity, cardiotoxicity, skin sensitization, kidney toxicity, eye irritation, and AMES toxicity, where calycosin has shown predicted toxicity against all except AMES toxicity. These are computational predictions, not confirmed human toxicity findings, and must be interpreted accordingly.

CYP450 Enzyme Interactions and Drug–Drug Interaction Potential

The predicted metabolic profile of calycosin reports it as a substrate for most CYP450 subunits, including CYP1A2, CYP2C9, and CYP2D6. A study specifically examining the interaction of calycosin with the cytochrome P450 system using five probe drugs (midazolam, tolbutamide, omeprazole, metoprolol, and phenacetin) concluded that caution is recommended, particularly when combining calycosin as a modality therapy with drugs metabolized by CYP1A2, CYP2D6, and CYP2C9, to reduce potential drug interactions. Drugs metabolized by these enzymes include a broad range of clinically important medications — anticoagulants, antidepressants, antidiabetics, antihypertensives, and others — making this interaction potential clinically relevant in individuals taking such medications alongside calycosin-containing products.

Estrogenic Activity: Considerations for Hormone-Sensitive Conditions

Because calycosin acts as a phytoestrogen capable of binding both ERα and ERβ, its use in individuals with hormone-sensitive conditions (such as estrogen receptor-positive breast cancer, endometriosis, or uterine fibroids) requires consideration. The context-dependent nature of its estrogenic activity — capable of exhibiting either estrogenic or anti-estrogenic effects depending on receptor subtype expression, concentration, and tissue — means that its net hormonal effect in an individual human is not straightforwardly predictable. Additional studies are still needed to make calycosin an applicable drug; the effects have to date been studied largely in animal models, and reliable and feasible human trials should be conducted.

Pharmacokinetic Limitations

The pharmacokinetics of calycosin require further clarification; currently, conjugation and oxidation of calycosin have been observed in zebrafish larvae, and more sophisticated and thorough studies on the in vivo metabolism of calycosin are important and required for the wider and improved application of this traditional drug.

State of Evidence and Need for Clinical Trials

Although the effectiveness of calycosin in experimental systems was reported, its mechanism has only been preliminarily established. Despite promising findings, the specific mechanism of action and its impact on different conditions remain poorly understood in humans. Some experimental studies of calycosin in numerous study models, including in silico, in vitro, preclinical, and clinical trials, have been conducted, but the scale and quality of available human clinical evidence remains very limited, and the compound has not achieved pharmaceutical approval in any jurisdiction.

Summary of Strength of Evidence

• Chemical identity and natural sources: Well established; multiple peer-reviewed sources agree.
• Traditional use (as part of Radix Astragali preparations): Historically documented; the isolated compound calycosin was not itself used traditionally.
• Anti-cancer activity: Extensive in vitro and animal data; human clinical evidence is lacking for the isolated compound.
• Anti-inflammatory effects: Strong mechanistic in vitro and animal evidence across multiple organ systems; no definitive human trials.
• Neuroprotection: Promising rodent model data; human evidence absent; BBB penetration is limited.
• Cardiovascular protection: In vitro and rodent evidence; no human trials.
• Bone health: In vitro and animal evidence for osteoblast stimulation and osteoclast suppression; human clinical outcomes not established.
• Antidiabetic / nephroprotective: Animal model and in vitro data; no controlled human trials identified.
• CYP450 drug interaction: Documented in animal probe-drug studies; warrants caution in combination with CYP1A2, CYP2C9, and CYP2D6 substrates.
• Safety in humans: Low toxicity reported in animal studies; human safety data insufficient to characterize the full risk profile.

References

• Sohel M et al. "Unveiling the potential anti-cancer activity of calycosin against multivarious cancers with molecular insights: A promising frontier in cancer research." Cancer Medicine, 2024. PMC10905684.
• Wikipedia. "Calycosin." (Accessed 2025).
• Gong Z et al. "Pharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus." Evidence-Based Complementary and Alternative Medicine, 2021. PMC8121564.
• Tian W et al. "Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the PI3K/AKT/mTOR Pathway." PMC6134888.
• Han F et al. "Exploring the multi-targeting phytoestrogen potential of Calycosin for cancer treatment: A review." PMC11062656.
• Emerging Role of Calycosin in Inflammatory Diseases: Molecular Mechanisms and Potential Therapeutic Applications. PMC12730483.
• Frontiers in Pharmacology. "A review of the botany, phytochemistry, traditional uses, pharmacology, toxicology, and quality control of the Astragalus membranaceus." 2023.
• Scientific Reports. "Red light-driven enhancement of calycosin biosynthesis in Astragalus membranaceus via functional characterization of AmI3'H." 2025.
• ScienceDirect. "Calycosin extracted from Astragalus membranaceus root inhibits platelet activation and thrombus formation." 2026.
• Gao J et al. "Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of Radix astragali." Pharmaceutical Biology, 2014.
• Peng S et al. "Calycosin Suppresses Breast Cancer Cell Growth via ERβ-Dependent Regulation of IGF-1R, p38 MAPK and PI3K/Akt Pathways." PLOS ONE, 2014. PMC3949755.
• Li M et al. "Calycosin inhibits oxidative stress-induced cardiomyocyte apoptosis via activating estrogen receptor-α/β." PubMed PMID: 26620254.
• Guo Y et al. "Calycosin suppresses colorectal cancer progression by targeting ERβ, upregulating PTEN, and inhibiting PI3K/Akt signal pathway." PubMed PMID: 35842774.
• Liu Z et al. "Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling." Journal of Experimental & Clinical Cancer Research, 2017.
• Ji M et al. "Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC-α/ERK1/2 pathway." PMC4758323.
• Chen B et al. "Calycosin inhibits migration and invasion through modulation of transforming growth factor beta-mediated mesenchymal properties in U87 and U251 cells." PMC4769008.
• Yin Y et al. "Calycosin Alleviates Doxorubicin-Induced Cardiotoxicity and Pyroptosis by Inhibiting NLRP3 Inflammasome Activation." PMC8754606.
• Astragalus Membranaceus—Can It Delay Cellular Aging? PMC12029721.
• Calycosin Ameliorates Neuroinflammation via TLR4-Mediated Signal Following Cerebral Ischemia/Reperfusion Injury in vivo and in vitro. PMC11645956.
• Calycosin attenuates the inflammatory damage of microglia induced by oxygen and glucose deprivation through the HMGB1/TLR4/NF-κB signaling pathway. PMC10520471.
• Zhang YY et al. "Calycosin Ameliorates Diabetes-Induced Renal Inflammation via the NF-κB Pathway In Vitro and In Vivo." Medical Science Monitor, 2019. PMC6413560.
• Zhang N et al. "Calycosin attenuates renal ischemia/reperfusion injury by suppressing NF-κB mediated inflammation via PPARγ/EGR1 pathway." Frontiers in Pharmacology, 2022. PMC9585199.
• PubMed. "The isoflavonoid calycosin inhibits inflammation and enhances beta cell function in gestational diabetes mellitus by suppressing RNF38 expression." PMID: 32538204.
• Dove Medical Press. "Calycosin Influences the Metabolism of Five Probe Drugs in Rats." Drug Design, Development and Therapy, 2020.
• Wu Y et al. "Calycosin: a Review of its Pharmacological Effects and Application Prospects." Expert Review of Anti-infective Therapy, 2021.
• Frontiers in Pharmacology. "Calycosin suppresses the activating effect of granulocyte-macrophage-colony-stimulating factor-producing T helper cells on macrophages in experimental atherosclerosis." 2025.
• PubMed. "Neuropharmacological effects of calycosin: a translational review of molecular mechanisms and therapeutic applications." PMID: 40237798.
• Liu P et al. "Anti-Aging Implications of Astragalus Membranaceus (Huangqi): A Well-Known Chinese Tonic." PMC5758356.
• Dove Medical Press. "Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents." Drug Design, Development and Therapy.